Supplementary MaterialsSupplementary Table 1 Assessment of baseline features according to median HbA1c reduction dmj-43-898-s001

Supplementary MaterialsSupplementary Table 1 Assessment of baseline features according to median HbA1c reduction dmj-43-898-s001. T2DM aged 20 to 70 years with glycosylated hemoglobin (HbA1c) amounts 7.0% and 9.5% were enrolled. Ipragliflozin (50 mg) was put into the backdrop therapy for these folks for 12 weeks. After three months treatment with ipragliflozin, the suggest HbA1c amounts had been reduced from 7.6% to 6.9% and 62.0% from the people reached the HbA1c focus on of significantly less than 7.0% (check for continuous variables as SW033291 well as the chi-square check for categorical variables. Multiple linear regression evaluation was SW033291 performed to recognize variables which were independently connected with a big change in the HbA1c level. Statistical analyses had been performed using PASW edition 18.0 (SPSS, Chicago, IL, USA). A valuevalue /th /thead Age?0.0550.524Female sex?0.0830.315HbA1c0.66 0.001HOMA-%0.1370.093Morning spot urine glucose/Cr?0.2990.001 Open in a separate window HbA1c, glycosylated hemoglobin; HOMA-, homeostasis model assessment of -cell function. Lastly, Spearman correlation analysis was performed to determine the association between HbA1c decrease and adjustments in medical and laboratory factors after ipragliflozin treatment, Nevertheless, no adjustable including a UGE modification was discovered to correlate having a modification in the HbA1c level (Supplementary Desk 3). DISCUSSION Inside our current single-arm multicenter prospective research of Korean people who have T2DM, we discovered that a 3-month treatment with ipragliflozin reduced 0.7% from the mean HbA1c amounts which 62.0% from the people reached the HbA1c focus on of significantly less than 7.0%. Furthermore, our analysis indicated that ipragliflozin treatment decreased not merely body bloodstream and weight pressure but also lipid guidelines. An increased baseline HbA1c worth was also an unbiased predictor for a larger decrease in the HbA1c level after ipragliflozin treatment. Furthermore, a lesser baseline UGE individually predicted an improved glucose-lowering efficacy of the 3-month treatment with ipragliflozin. Earlier studies have analyzed the relationship between your renal threshold for blood sugar reabsorption or UGE with SGLT2 inhibitor treatment and its own glucose-lowering effectiveness in people who have T2DM [6,7]. Within an previous research of 20 Japanese people who have T2DM, the bloodstream and UGE sugar levels had been assessed before and many hours after an individual dosage of dapagliflozin, which was discovered to become more effective in young people. The writers speculated that was because young people have an increased UGE than the elderly and that is actually a marker for an improved glucose-lowering response for an SGLT2 inhibitor [6]. However Notably, another Japanese research of 22 people who have T2DM found a different summary. In that record, the median improvement in HbA1c ideals after a 1-season treatment with ipragliflozin was ?0.5% and there is a substantial inverse correlation found between your renal threshold for glucose reabsorption as well as the improvement in the HbA1c level ( em r /em =?0.601, em P /em =0.003) [7]. The writers speculated that as people with an increased renal threshold for glucose reabsorption possess a greater capability to reabsorb urinary glucose from the proximal tubule, these people may excrete a smaller amount of glucose into the urine [7]. In partial agreement with the aforementioned Japanese study [7], ipragliflozin showed a better glucose-lowering efficacy in our present study subjects with a lower baseline UGE. In addition, it is well recognized that people with diabetes have increased SGLT2 expression and activity [8] and hence that glycosuria SW033291 does not arise in diabetics at Rabbit Polyclonal to CKI-gamma1 the plasma glucose levels that would normally cause the excretion of glucose to urine in non-diabetic individuals [9]. Therefore, the lower baseline UGE in our better ipragliflozin response group might be due to increased SGLT2 expression and/or activity. Similarly, another independent predictor of a higher baseline HbA1c value could be associated with increased SGLT2 expression and/or activity. Collectively, increased SGLT2 expression and/or activity caused by hyperglycemia and the consequent decrease in the UGE level might be a marker for a better response to SGLT2 inhibitors in people with T2DM. Another explanation for a lower baseline UGE as a marker for better response to SGLT2 inhibitors is that confounding caused by baseline HbA1c. In this study, there was a positive.